Paper Details

  1. Home
  2. Paper Details

Penicillamine in rheumatoid arthritis. A problem of toxicity.

Author: SamantaA, TaylorH G

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Penicillamine, a disease-modifying antirheumatic drug, is effective in treating rheumatoid arthritis but its use is limited by toxicity. Common adverse effects include proteinuria, skin rashes, gastrointestinal events, and thrombocytopenia or leucopenia.
Paper Details　
Original Abstract of the Article :
Penicillamine has proved an effective second line agent in rheumatoid arthritis. Its use, however, is limited by its toxicity. Long term studies show that only between 30 and 40% of patients started on penicillamine are still taking the drug at 2 years. Toxicity is the chief reason for stopping trea...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2165/00002018-199207010-00006

データ提供：米国国立医学図書館（NLM）

Penicillamine in Rheumatoid Arthritis: A Problem of Toxicity

This study delves into the [rheumatology] field and examines the use of penicillamine, a disease-modifying antirheumatic drug (DMARD), in the treatment of rheumatoid arthritis. The study highlights the effectiveness of penicillamine as a second-line agent for rheumatoid arthritis, but also emphasizes the importance of managing its potential toxicity. The researchers found that penicillamine is associated with various adverse effects, including proteinuria, skin rashes, gastrointestinal events, and thrombocytopenia or leucopenia. The study also notes that certain genetic factors can increase the risk of developing penicillamine toxicity.

Navigating the Risks and Benefits of Penicillamine

This study underscores the importance of carefully monitoring patients receiving penicillamine therapy to minimize the risk of toxicity. The study's findings highlight the complex nature of DMARD therapy and the need for careful consideration of the potential benefits and risks for each patient.

Balancing Treatment Efficacy and Safety

This research reminds us that the desert of rheumatoid arthritis can be challenging to navigate. Penicillamine, while an effective DMARD, carries significant risks that must be carefully managed. This study emphasizes the need for a balanced approach that prioritizes both treatment efficacy and patient safety.

Dr.Camel's Conclusion

Rheumatoid arthritis can be a real camel breaker, making it difficult to move through the desert of life. This research highlights the need to carefully consider the risks and benefits of penicillamine therapy in rheumatoid arthritis. It's like navigating a treacherous oasis in the desert, where the water can be both life-giving and dangerous.
Date :
  1. Date Completed 1992-04-02
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

1536698

DOI: Digital Object Identifier

10.2165/00002018-199207010-00006

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.